Key Highlights

  • Positive trailing Earnings at a price to earnings ratio of 3.99 on Diluted Earnings per Share of USD 2.10.
  • Technical, Moving Average and oscillator rating groups all read positive.
  • Up 16.53 per cent over six months against a 28.96 per cent decline year to date.

Technical position

RSI 14 reads 56.51, above the 50 line but well clear of the conventional 70 overbought threshold. Ten-period momentum sits at 1.29 and the Awesome Oscillator at 0.46, both positive. The Commodity Channel index reads 106.13, just above the 100 line, while the stochastic sits at 69.68 on %K against 65.48 on %D. That leaves the stock less extended on short-term oscillators than most names carrying a comparable CCI reading. The technical rating is Buy, the moving average rating Strong buy and the oscillator rating Buy, with the 21-period exponential moving average holding above the 50-period average.

Fundamental snapshot

CorMedix sits in health technology with a Market Capitalisation of USD 653.95 million. The shares last traded at USD 8.39, down 1.99 per cent on the session. Trailing diluted earnings per share of USD 2.10 gives a price to earnings ratio of 3.99, with earnings per share growth of 181.85 per cent year on year. No Dividend is paid. Analyst consensus reads Strong buy.

Price performance

The stock is up 1.08 per cent over one week and 4.88 per cent over one month, with a 16.53 per cent gain over six months. It is down 0.47 per cent over three months, 28.96 per cent year to date, 38.89 per cent over one year and 47.56 per cent on an all time basis. One month Volatility reads 4.93 per cent, and turnover of 865,510 shares is running below its recent average.

This article is general information only and does not take into account any individual objectives, financial situation or needs. It is not a recommendation to buy, sell or hold any security. All details are as stated in the company announcement or third party research referenced and are subject to change. Past performance is not a reliable indicator of future performance. Investors should consider the appropriateness of any information having regard to their own circumstances and seek independent financial advice before making any financial decision.